Featured Article

Dupixent and Xolair are both approved medications used to treat moderate-to-severe forms of asthma and atopic dermatitis.

Both medications are monoclonal antibodies, designed to work differently from other asthma and eczema treatments. Monoclonal antibodies work by targeting specific proteins in the immune system. They can modify or suppress the immune system's activity to reduce inflammation, itching, and other asthma and eczema symptoms.

Dupixent is a medicine used to treat adults and adolescents 12 years of age and over with active, uncontrolled moderate-to-severe atopic dermatitis. It is also used for adults with inadequately-controlled, moderate-to-severe asthma when there is a type 2 inflammatory component. Dupixent can be used with or without corticosteroid medicines, and is taken as an injection under the skin every other week.

Xolair is a medicine used to treat moderate-to-severe asthma in adolescents and adults 12 years of age and older. It is used when asthma is not adequately controlled by an inhaled corticosteroid medicine. Xolair is given once every two to four weeks as an injection under the skin.

Though both medications are effective in treating asthma and atopic dermatitis, they have some differences. Dupixent is approved to treat moderate-to-severe eczema, while Xolair is only for treating asthma. Xolair is also given less often than Dupixent, though both require injections under the skin. Additionally, Dupixent can be used with or without corticosteroid medicines, while Xolair should only be used in addition to an inhaled corticosteroid treatment.

Overall, Dupixent and Xolair can both be effective in treating moderate-to-severe asthma and atopic dermatitis. However, they each have their own set of differences, so it is important to talk to your doctor about which one might be the best option for you.